Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.54 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.54 |
| ▸ | QPCT | Q16769 | 1/20 | 0.52 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26399531 | 1.00 | EPHX1 (0.61) | EPHX1CYP3A4CYP2D6TSHRCYP2C19 | |
| SCHEMBL17481128 | 0.84 | CYP3A4 (0.82) | EPHX1CYP3A4CYP2D6TSHRCYP2C19 | |
| SCHEMBL14415981 | 0.82 | HRH3 (0.64) | EPHX1HRH3HRH4 | |
| SCHEMBL18381205 | 0.79 | CYP3A4 (0.74) | CYP3A4CYP2D6TSHRCYP2C19LMNA | |
| SCHEMBL17481134 | 0.79 | CYP3A4 (0.78) | EPHX1CYP3A4CYP2D6TSHRCYP2C19 | |
| SCHEMBL17483163 | 0.79 | CYP3A4 (0.78) | CYP3A4CYP2D6TSHRCYP2C19LMNA | |
| SCHEMBL19051464 | 0.78 | EPHX1 (0.68) | EPHX1CYP3A4CYP2D6TSHRCYP2C19 | |
| SCHEMBL25670592 | 0.78 | CYP3A4 (0.72) | EPHX1CYP3A4CYP2D6TSHRCYP2C19 | |
| SCHEMBL29419585 | 0.77 | CYP3A4 (0.76) | CYP3A4CYP2D6TSHRCYP2C19LMNA | |
| SCHEMBL17481127 | 0.77 | CYP3A4 (0.74) | EPHX1CYP3A4CYP2D6TSHRCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312630-A1 | PHOSPHORAMIDITE SYNTHESIS ON-DEMAND | AARHUS UNIVERSITET (DK) | 2023-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312630-A1 | PHOSPHORAMIDITE SYNTHESIS ON-DEMAND | RNGTT, PPA1, PNP | EPHX1 659/4885CYP3A4 3930/4885CYP2D6 4170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.